Evidence map›Paper›PMID 40268657›Full record

ReviewTrends in immunology2025

mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation.

Byron Brook, Morgan Goetz, Valerie Duval, Romain Micol, David J Dowling

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Byron BrookPrecision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Morgan GoetzPrecision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Valerie DuvalCombined Therapeutics Incorporated, Boston, MA 02135, USA.
Romain MicolCombined Therapeutics Incorporated, Boston, MA 02135, USA.
David J DowlingPrecision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: david.dowling@childrens.harvard.edu.

Funding

Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
VACCINE ADJUVANT DISCOVERY PROGRAM (VADP)75N93024C00020 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2024 to 2025
$2.5M
NIAID NIH HHS 75N93019C00044NIAID NIH HHS 75N93024C00020
6 · The paper itself

Abstract

The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.

Indexed as

COVID-19COVID-19 VaccinesMicroRNAsmRNA VaccinesRNA, MessengerSARS-CoV-22019-nCoV Vaccine mRNA-1273Adjuvants, ImmunologicAnimalsBNT162 VaccineHumansLipidsLiposomesNanoparticlesTissue Distribution2019-nCoV Vaccine mRNA-1273Adjuvants, ImmunologicBNT162 VaccineCOVID-19 VaccinesLipid NanoparticlesLipidsLiposomesMicroRNAsmRNA VaccinesRNA, MessengeradjuvantsbiodistributionmicroRNAmRNA vaccines

Identifiers

PMID40268657
PMCPMC12351375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.